# Biomarker-guided IL-5 blockade achieves steroid-free MPO-ANCA seroconversion in EGPA

## TL;DR

A case study shows that using a biomarker to guide treatment with mepolizumab helped achieve recovery in EGPA without steroids.

## Contribution

Demonstrates a steroid-free treatment approach for MPO-ANCA positive EGPA using biomarker-guided therapy.

## Key findings

- Early mepolizumab treatment guided by biomarkers led to MPO-ANCA seroconversion in a patient with EGPA.
- The treatment achieved remission without the need for steroids in a confirmed EGPA case.

## Abstract

This report describes a case of biopsy-confirmed EGPA in which early initiation of mepolizumab, guided by biomarker surveillance, resulted in steroid-free MPO-ANCA seroconversion. These findings suggest a potential steroid-sparing strategy for ANCA-positive EGPA.